Ross Muken
Stock Analyst at Evercore ISI Group
(2.01)
# 3,087
Out of 4,996 analysts
46
Total ratings
56%
Success rate
0.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Outperform | $180 → $190 | $148.56 | +27.89% | 8 | Aug 8, 2025 | |
| HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $66.04 | +6.00% | 10 | Aug 6, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $163.79 | +46.53% | 9 | Jul 25, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $123.39 | +5.36% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $43.90 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $153.71 | -56.41% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $91.69 | +172.66% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $464.24 | -52.61% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $13.85 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Aug 8, 2025
Maintains: Outperform
Price Target: $180 → $190
Current: $148.56
Upside: +27.89%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $66.04
Upside: +6.00%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $163.79
Upside: +46.53%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $123.39
Upside: +5.36%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $43.90
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $153.71
Upside: -56.41%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $91.69
Upside: +172.66%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $464.24
Upside: -52.61%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $13.85
Upside: -